T1	p 54 102	previously untreated advanced breast cancer -- a
T2	p 643 697	previously untreated metastatic breast cancer patients
T3	p 1258 1521	Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 . Patients could not have had prior chemotherapy for metastatic disease . Prior adjuvant chemotherapy was permitted . Patients could not have visceral crisis .
T4	p 2284 2329	previously untreated breast cancer patients .
T5	i 6 17	Amonafide :
T6	i 154 163	Amonafide
T7	i 498 507	Amonafide
T8	i 788 840	standard cyclophosphamide-doxorubicin-5-fluorouracil
T9	i 849 928	immediate treatment with standard cyclophosphamide-doxorubicin-5-fluorouracil .
T10	i 1133 1142	amonafide
T11	i 1186 1229	cyclophosphamide-doxorubicin-5-fluorouracil
T12	i 1522 1531	Amonafide
T13	i 2252 2261	amonafide
T14	o 988 1030	survival , toxicity , and overall response
T15	o 1701 1715	hematotoxicity
T16	o 1734 1742	Toxicity
T17	o 1794 1817	grade 3 or 4 leukopenia
T18	o 1831 1862	grade 3 or 4 thrombocytopenia ;
T19	o 1875 1885	leukopenia
T20	o 1902 1920	thrombocytopenia .
T21	o 1925 1938	response rate
T22	o 2014 2036	hematological toxicity
T23	o 2083 2093	leukopenia
T24	o 2151 2159	response
T25	o 2176 2192	thrombocytopenia
T26	o 2345 2370	steep dose-response curve
T27	o 2418 2434	myelosuppression
T28	o 2450 2468	Rates of responses